JP2006526011A - セリンプロテアーゼ（特に、ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼ）のインヒビター - Google Patents

セリンプロテアーゼ（特に、ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼ）のインヒビター Download PDF

Info

Publication number
JP2006526011A
JP2006526011A JP2006509873A JP2006509873A JP2006526011A JP 2006526011 A JP2006526011 A JP 2006526011A JP 2006509873 A JP2006509873 A JP 2006509873A JP 2006509873 A JP2006509873 A JP 2006509873A JP 2006526011 A JP2006526011 A JP 2006526011A
Authority
JP
Japan
Prior art keywords
aliphatic
optionally
compound
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006509873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006526011A5 (enExample
Inventor
ルーク ジェイ． ファーマー，
ロバート ピー． ペルニ，
ゴビンダ ラオ ビセッティ，
キース ピー． ウィルソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/412,600 external-priority patent/US7273885B2/en
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2006526011A publication Critical patent/JP2006526011A/ja
Publication of JP2006526011A5 publication Critical patent/JP2006526011A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2006509873A 2003-04-11 2004-04-09 セリンプロテアーゼ（特に、ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼ）のインヒビター Pending JP2006526011A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/412,600 US7273885B2 (en) 2002-04-11 2003-04-11 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US51376503P 2003-10-23 2003-10-23
PCT/US2004/011012 WO2004092162A1 (en) 2003-04-11 2004-04-09 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010243570A Division JP2011068655A (ja) 2003-04-11 2010-10-29 セリンプロテアーゼ（特に、ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼ）のインヒビター

Publications (2)

Publication Number Publication Date
JP2006526011A true JP2006526011A (ja) 2006-11-16
JP2006526011A5 JP2006526011A5 (enExample) 2007-05-31

Family

ID=33302781

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006509873A Pending JP2006526011A (ja) 2003-04-11 2004-04-09 セリンプロテアーゼ（特に、ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼ）のインヒビター
JP2010243570A Pending JP2011068655A (ja) 2003-04-11 2010-10-29 セリンプロテアーゼ（特に、ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼ）のインヒビター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010243570A Pending JP2011068655A (ja) 2003-04-11 2010-10-29 セリンプロテアーゼ（特に、ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼ）のインヒビター

Country Status (10)

Country Link
US (3) US20050090450A1 (enExample)
EP (2) EP1636208B1 (enExample)
JP (2) JP2006526011A (enExample)
CN (1) CN100453553C (enExample)
AR (1) AR044513A1 (enExample)
AT (1) ATE547412T1 (enExample)
AU (1) AU2004230946A1 (enExample)
CA (1) CA2521678A1 (enExample)
ES (1) ES2381548T3 (enExample)
WO (1) WO2004092162A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007532474A (ja) * 2003-10-10 2007-11-15 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特にｈｃｖのｎｓ３−ｎｓ４ａプロテアーゼの阻害剤

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1133649C (zh) 1996-10-18 2004-01-07 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是丙型肝炎病毒ns3蛋白酶的抑制剂
ATE297946T1 (de) * 2000-04-03 2005-07-15 Vertex Pharma Inhibitoren von serin proteasen, speziell der hepatitis-c-virus ns3-protease
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
PL373399A1 (en) * 2002-04-11 2005-08-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
CN102020700A (zh) * 2003-07-18 2011-04-20 沃泰克斯药物股份有限公司 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
MY148123A (en) * 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1664091A1 (en) 2003-09-18 2006-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7365092B2 (en) * 2003-10-10 2008-04-29 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CN1938332B (zh) * 2004-02-04 2011-10-19 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
NZ563909A (en) 2005-05-13 2011-10-28 Virochem Pharma Inc Thiophene derivatives and their use for the treatment or prevention of flavivirus infections
EP2402331A1 (en) * 2005-08-02 2012-01-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
KR20140098867A (ko) 2005-11-11 2014-08-08 버텍스 파마슈티칼스 인코포레이티드 Ｃ형 간염 바이러스 변이체
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
US8039475B2 (en) 2006-02-27 2011-10-18 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
KR20080112303A (ko) 2006-03-16 2008-12-24 버텍스 파마슈티칼스 인코포레이티드 중수소화 ｃ형 간염 프로테아제 억제제
WO2007111866A2 (en) * 2006-03-23 2007-10-04 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
NZ576780A (en) 2006-11-15 2011-12-22 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of flavivirus infections
EP2134717A2 (en) * 2007-02-27 2009-12-23 Vertex Pharmceuticals Incorporated Inhibitors of serine proteases
PT2114924E (pt) * 2007-02-27 2012-04-03 Vertex Pharma Co-cristais e composições farmacêuticas que compreendem os mesmos
US20090004140A1 (en) * 2007-06-26 2009-01-01 Yao-Ling Qiu 4-substituted pyrrolidine as anti-infectives
US20090022689A1 (en) * 2007-07-18 2009-01-22 Yat Sun Or C4-spiro-pyrrolidine antivirals
JP5443360B2 (ja) 2007-08-30 2014-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド 共結晶体およびそれを含む医薬組成物
US20090060874A1 (en) * 2007-09-05 2009-03-05 Yao-Ling Qiu Bicyclic pyrrolidine derivatives
TW200936131A (en) 2008-02-04 2009-09-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US20090233972A1 (en) * 2008-03-12 2009-09-17 Yat Sun Or Substituted heterocycles as anti-infectives
US20090324544A1 (en) * 2008-06-11 2009-12-31 Yao-Ling Qiu Substituted cyclic pyrrolidine derivatives
US20090326019A1 (en) * 2008-06-11 2009-12-31 Yat Sun Or 3,4-bicyclic pyrrolidine antivirals
US20100074863A1 (en) * 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
EP2403860B1 (en) 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8980920B2 (en) 2009-05-29 2015-03-17 Merck Sharp & Dohme Corp. Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
EP2477980B1 (en) 2009-09-15 2016-06-08 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
AU2010326225A1 (en) 2009-11-25 2012-06-07 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
EP2503881B1 (en) 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
AR079528A1 (es) 2009-12-18 2012-02-01 Idenix Pharmaceuticals Inc Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
CA2784036A1 (en) 2009-12-24 2011-06-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US8609635B2 (en) 2010-03-09 2013-12-17 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
WO2011119860A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119858A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
CA2794145A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
AU2011232348A1 (en) 2010-03-24 2012-10-11 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of Flavivirus infections
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
EP2582717A2 (en) 2010-06-15 2013-04-24 Vertex Pharmaceuticals Incorporated Hcv ns5b polymerase mutants
EP2585448A1 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
MX2012014918A (es) 2010-06-28 2013-04-08 Vertex Pharma Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus.
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
AU2011286276A1 (en) 2010-07-26 2013-01-24 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
AU2011292040A1 (en) 2010-08-17 2013-03-07 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flaviviridae viral infections
CA2812779A1 (en) 2010-09-29 2012-04-19 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EA201391519A1 (ru) 2011-04-13 2014-03-31 Мерк Шарп И Доум Корп. 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013016501A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Formulations of thiophene compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
WO2013072328A1 (en) 2011-11-14 2013-05-23 Sanofi Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
KR102161077B1 (ko) * 2012-06-29 2020-09-29 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP3063140A4 (en) 2013-10-30 2017-11-08 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
WO2017222915A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Heterocyclic prolinamide derivatives
EP3472151A4 (en) 2016-06-21 2020-03-04 Orion Ophthalmology LLC CARBOCYCLIC PROLINAMIDE DERIVATIVES
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017679A1 (en) * 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO1998046630A1 (en) * 1997-04-16 1998-10-22 Peptide Therapeutics Limited Hepatitis c ns3 protease inhibitors
WO1999050230A1 (en) * 1998-03-31 1999-10-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO2001040262A1 (en) * 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
WO2001074768A2 (en) * 2000-04-03 2001-10-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US534410A (en) * 1895-02-19 Sylvania
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
NZ235155A (en) * 1989-09-11 1993-04-28 Merrell Dow Pharma Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
EP0564561A4 (en) * 1990-12-28 1994-08-10 Georgia Tech Res Inst Peptides ketoamides, ketoacids, and ketoesters
US5384410A (en) 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
GB9623908D0 (en) * 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
CN1196687C (zh) 1999-03-19 2005-04-13 沃泰克斯药物股份有限公司 Impdh酶抑制剂
AU5788800A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
SI1385870T1 (sl) 2000-07-21 2010-08-31 Schering Corp Peptidi kot NS3-serin proteazni inhibitorji virusa hepatitisa C
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
EP1301527A2 (en) * 2000-07-21 2003-04-16 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
PL373399A1 (en) * 2002-04-11 2005-08-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017679A1 (en) * 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO1998046630A1 (en) * 1997-04-16 1998-10-22 Peptide Therapeutics Limited Hepatitis c ns3 protease inhibitors
WO1999050230A1 (en) * 1998-03-31 1999-10-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO2001040262A1 (en) * 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
WO2001074768A2 (en) * 2000-04-03 2001-10-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007532474A (ja) * 2003-10-10 2007-11-15 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特にｈｃｖのｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
JP2011246487A (ja) * 2003-10-10 2011-12-08 Vertex Pharmaceuticals Inc セリンプロテアーゼ、特にｈｃｖのｎｓ３−ｎｓ４ａプロテアーゼの阻害剤

Also Published As

Publication number Publication date
CN1795188A (zh) 2006-06-28
EP1636208A1 (en) 2006-03-22
WO2004092162A1 (en) 2004-10-28
ES2381548T3 (es) 2012-05-29
EP2332935A1 (en) 2011-06-15
AU2004230946A1 (en) 2004-10-28
CA2521678A1 (en) 2004-10-28
US20050090450A1 (en) 2005-04-28
US8618152B2 (en) 2013-12-31
CN100453553C (zh) 2009-01-21
HK1090644A1 (zh) 2006-12-29
US20090022688A1 (en) 2009-01-22
EP1636208B1 (en) 2012-02-29
ATE547412T1 (de) 2012-03-15
US20120014914A1 (en) 2012-01-19
AR044513A1 (es) 2005-09-14
JP2011068655A (ja) 2011-04-07

Similar Documents

Publication Publication Date Title
US8618152B2 (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases
JP4745230B2 (ja) セリンプロテアーゼ、特に、ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
US20040018986A1 (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7906550B2 (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
JP4685775B2 (ja) セリンプロテアーゼ、とりわけｈｃｖｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
JP4767852B2 (ja) セリンプロテアーゼ、特にｈｃｖｎｓ３‐ｎｓ４ａの阻害剤
WO2005007681A9 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
AU2011203054B2 (en) Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
HK1090644B (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
HK1144824A (zh) 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
HK1098164B (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
HK1081196B (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090519

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090616

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090722

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090824

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100629